Table 2.

Number (%) of patients in the trial who were on different antihypertensive treatments according to follow-up SBP, DBP, MAP, and pulse pressure above or below the median

ParameterSBPDBPMAPPulse Pressure
BelowAboveBelowAboveBelowAboveBelowAbove
ACEi yes329 (55.6)263 (44.7)a325 (55.1)267 (45.3)a341 (57.7)251 (42.6)a308 (52.4)284 (48.0)
ndCCB yes298 (50.3)292 (49.7)307 (52.0)283 (48.0)307 (52.0)283 (48.0)292 (49.7)298 (50.3)
Veratran161 (27.2)132 (22.5)170 (28.8)123 (20.9)b174 (29.4)119 (20.2)a147 (25.0)146 (24.7)
Trandolapril168 (28.4)131 (22.3)c155 (26.3)144 (24.4)167 (28.3)132 (22.4)c161 (27.4)138 (23.3)
Verapamil137 (23.1)160 (27.2)137 (23.2)160 (27.1)133 (22.5)164 (27.8)c145 (24.7)152 (25.7)
Placebo126 (21.3)165 (28.1)b128 (21.7)163 (27.6)c117 (19.8)174 (29.5)a135 (23.0)156 (26.4)
Diuretic87 (14.7)142 (24.2)a100 (17.0)129 (21.9)c84 (14.2)145 (24.6)a99 (16.8)130 (22.0)c
β blocker42 (7.1)61 (10.4)c44 ( 7.5)59 (10.0)45 (7.6)58 (9.9)43 ( 7.3)60 (10.1)
dCCB84 (14.2)243 (41.3)a121 (20.5)206 (34.9)a79 (13.4)248 (42.1)a112 (19.1)215 (36.3)a
Sympatholytic agent179 (30.2)378 (64.3)a202 (34.2)355 (60.2)a174 (29.4)383 (65.0)a211 (35.9)346 (58.5)a
  • a P ≤ 0.001,

  • b P ≤ 0.01,

  • c P < 0.05 versus below.